Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TransMedics Group, Inc.TMDX · Entity 4261 | Chief Commercial Officer | March 03, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TransMedics Group, Inc.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,042 |
Reported balance
After 2025-03-03 transaction · row 1
1 source rowRow 1 · 2025-03-03 · Sale · Disposed 2,407 · Balance 36,042 F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 116 | $161.99 | $18,790.84 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 14 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,973 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F12 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $161.67 to $162.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 126 | $161.09 | $20,297.34 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 13 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,089 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F11 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $160.63 to $161.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 329 | $159.86 | $52,593.94 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 12 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,215 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F10 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $159.47 to $160.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 240 | $158.88 | $38,131.20 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 11 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,544 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $158.39 to $159.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 252 | $157.83 | $39,773.16 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,784 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $157.39 to $158.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 124 | $157.00 | $19,468.00 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,036 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $156.29 to $157.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 380 | $155.69 | $59,162.20 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 8 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,160 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $155.28 to $156.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 510 | $154.86 | $78,978.60 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 7 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,540 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $154.27 to $155.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 483 | $153.81 | $74,290.23 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,050 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $153.24 to $154.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 154 | $152.71 | $23,517.34 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,533 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $152.20 to $153.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 114 | $151.80 | $17,305.20 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,687 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $151.19 to $152.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,083 | $13.28 | $14,382.24 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 417 | $66.10 | $27,563.70 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,458 | $38.46 | $56,074.68 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,083 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · derivative · entry 11 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,667 Underlying: Common Stock · 1,083 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F9 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · derivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,349 Underlying: Common Stock · 417 shares Expires 2033-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 20, 2027. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,458 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · derivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,667 Underlying: Common Stock · 1,458 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 24, 2025. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 160 | $153.48 | $24,556.80 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · nonDerivative · entry 8 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $153.04 to $153.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 582 | $152.53 | $88,772.46 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · nonDerivative · entry 7 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,003 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $152.00 to $152.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,106 | $151.33 | $167,370.98 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · nonDerivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,585 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $151.00 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,000 | $150.70 | $150,700.00 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,691 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $150.00 to $150.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 110 | $149.57 | $16,452.70 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,691 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $149.00 to $149.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,083 | $13.28 | $14,382.24 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 417 | $66.10 | $27,563.70 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,458 | $38.46 | $56,074.68 |
DisclosureSEC source: 0000950170-24-081567 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,084 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · derivative · entry 13 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,750 Underlying: Common Stock · 1,084 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F11 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · derivative · entry 12 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,766 Underlying: Common Stock · 417 shares Expires 2033-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F10 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 20, 2027. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,459 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · derivative · entry 11 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 1,459 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F9 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 24, 2025. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 457 | $135.97 | $62,138.29 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $135.37 to $136.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 152 | $134.66 | $20,468.32 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,300 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $134.33 to $135.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 567 | $133.67 | $75,790.89 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 8 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,452 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $133.31 to $134.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 921 | $132.71 | $122,225.91 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 7 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,019 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $132.315 to $133.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 539 | $131.87 | $71,077.93 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,940 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $131.30 to $132.295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 219 | $130.79 | $28,643.01 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,479 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $130.315 to $131.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 105 | $129.92 | $13,641.60 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,698 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $129.30 to $130.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,084 | $13.28 | $14,395.52 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 417 | $66.10 | $27,563.70 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,459 | $38.46 | $56,113.14 |
DisclosureSEC source: 0000950170-24-069423 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 06, 2024 Filed May 8, 2024 16:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,839 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0000950170-24-055795 · ownership.xml · derivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,183 Underlying: Common Stock · 5,839 shares Expires 2033-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following February 20, 2023 until the option is fully vested on February 20, 2027. Read SEC document |
| May 06, 2024 Filed May 8, 2024 16:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 5,839 | $130.07 | $759,478.73 |
DisclosureSEC source: 0000950170-24-055795 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,792 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $130.00 to $130.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 06, 2024 Filed May 8, 2024 16:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 5,839 | $66.10 | $385,957.90 |
DisclosureSEC source: 0000950170-24-055795 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,083 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · derivative · entry 24 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,834 Underlying: Common Stock · 1,083 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F18 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,458 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · derivative · entry 23 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,584 Underlying: Common Stock · 1,458 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F17 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,326 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · derivative · entry 22 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,042 Underlying: Common Stock · 45,326 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F17 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 7,388 | $120.01 | $886,633.88 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 20 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By the Khayal Family 2021 Irrevocable Trust Disclosed balance after: 0 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F16 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $120.00 to $120.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 500 | $111.50 | $55,750.00 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 19 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By the Khayal Family 2021 Irrevocable Trust Disclosed balance after: 7,388 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F15 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $111.41 to $111.6375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 6,888 | $110.06 | $758,093.28 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 18 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By the Khayal Family 2021 Irrevocable Trust Disclosed balance after: 7,888 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F14 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $110.00 to $110.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $123.66 | $12,366.00 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 17 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,792 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F13 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $123.64 to $123.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 17 | $122.51 | $2,082.67 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 16 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,892 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 532 | $121.74 | $64,765.68 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 15 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,909 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F12 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $121.43 to $122.355, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.